IMMUNOVIA AB Financials Immunovia AB London S.E.
Equities
0G8X
SE0006091997
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.4 SEK | -96.26% |
|
-.--% | -22.82% |
| 04-29 | Transcript : Immunovia AB, Q1 2024 Earnings Call, Apr 29, 2024 | |
| 04-29 | Immunovia Streamlines Lab Operations with Move to Research Triangle Park, North Carolina | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 2,691 | 3,530 | 2,698 | 1,697 | 595.2 | 80.25 |
| Enterprise Value (EV) 1 | 2,305 | 3,304 | 2,262 | 1,443 | 526.7 | 7.747 |
| P/E ratio | -29.5 x | -30.7 x | -17.4 x | -10.9 x | -3.54 x | -0.22 x |
| Yield | - | - | - | - | - | - |
| Capitalization / Revenue | 106 x | 9,916 x | 7,452 x | 2,011 x | 520 x | 51 x |
| EV / Revenue | 90.8 x | 9,282 x | 6,250 x | 1,710 x | 460 x | 4.92 x |
| EV / EBITDA | -27 x | -29.9 x | -17.3 x | -8.96 x | -2.84 x | -0.05 x |
| EV / FCF | -25.9 x | -38.8 x | -19.1 x | -12.5 x | -5.04 x | -0.23 x |
| FCF Yield | -3.86% | -2.58% | -5.23% | -8.01% | -19.8% | -437% |
| Price to Book | 5.83 x | 9.87 x | 4.5 x | 3.91 x | 2.44 x | 1.2 x |
| Nbr of stocks (in thousands) | 19,531 | 19,655 | 22,632 | 22,632 | 22,632 | 45,287 |
| Reference price 2 | 137.8 | 179.6 | 119.2 | 75.00 | 26.30 | 1.772 |
| Announcement Date | 04/03/19 | 20/03/20 | 12/03/21 | 10/03/22 | 21/04/23 | 29/04/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 25.38 | 0.356 | 0.362 | 0.844 | 1.145 | 1.575 |
| EBITDA 1 | -85.45 | -110.5 | -130.4 | -161.1 | -185.2 | -170 |
| EBIT 1 | -88.23 | -114.4 | -134.7 | -166.7 | -191.2 | -296.7 |
| Operating Margin | -347.58% | -32,120.79% | -37,203.87% | -19,756.04% | -16,699.48% | -18,837.27% |
| Earnings before Tax (EBT) 1 | -86.53 | -114.5 | -146 | -156 | -168.1 | -309.4 |
| Net income 1 | -86.54 | -114.5 | -146 | -156 | -168.1 | -309.4 |
| Net margin | -340.91% | -32,168.82% | -40,340.61% | -18,479.38% | -14,680.52% | -19,646.92% |
| EPS 2 | -4.666 | -5.852 | -6.843 | -6.892 | -7.430 | -7.950 |
| Free Cash Flow 1 | -89.05 | -85.21 | -118.4 | -115.6 | -104.5 | -33.85 |
| FCF margin | -350.8% | -23,936.38% | -32,697.51% | -13,695.63% | -9,128.88% | -2,149.08% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 04/03/19 | 20/03/20 | 12/03/21 | 10/03/22 | 21/04/23 | 29/04/24 |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|
| Net sales 1 | 0.344 | - | 0.108 | 0.381 |
| EBITDA 1 | -44.68 | - | -44.45 | -35.78 |
| EBIT 1 | -50.88 | - | -50.79 | -41.92 |
| Operating Margin | -14,789.83% | - | -47,025% | -11,001.57% |
| Earnings before Tax (EBT) 1 | -47.13 | - | -33.73 | -22.93 |
| Net income 1 | -47.13 | - | -33.73 | -22.93 |
| Net margin | -13,700.29% | - | -31,227.78% | -6,018.9% |
| EPS 2 | -2.080 | -1.950 | -1.490 | -1.010 |
| Dividend per Share | - | - | - | - |
| Announcement Date | 17/02/22 | 28/04/22 | 24/08/22 | 10/11/22 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 386 | 226 | 435 | 254 | 68.5 | 72.5 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | -89 | -85.2 | -118 | -116 | -105 | -33.8 |
| ROE (net income / shareholders' equity) | -24.8% | -27.9% | -30.5% | -30.2% | -49.6% | -199% |
| ROA (Net income/ Total Assets) | -15.1% | -15.9% | -15.6% | -18% | -30.1% | -92.9% |
| Assets 1 | 571.3 | 718.5 | 937.3 | 864.3 | 558.7 | 333.1 |
| Book Value Per Share 2 | 23.70 | 18.20 | 26.50 | 19.20 | 10.80 | 1.480 |
| Cash Flow per Share 2 | 19.80 | 13.40 | 20.70 | 12.70 | 4.690 | 1.700 |
| Capex 1 | 9.06 | 6.03 | 4 | 3.1 | 1.26 | - |
| Capex / Sales | 35.68% | 1,694.94% | 1,104.42% | 367.42% | 109.69% | - |
| Announcement Date | 04/03/19 | 20/03/20 | 12/03/21 | 10/03/22 | 21/04/23 | 29/04/24 |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -42.86% | 2.82B | |
| +20.51% | 1.91B | |
| -1.13% | 1.65B | |
| +27.00% | 1.25B | |
| -14.07% | 988M | |
| -20.60% | 910M | |
| +0.88% | 786M | |
| -24.34% | 634M | |
| +8.73% | 507M |
- Stock Market
- Equities
- IMMNOV Stock
- 0G8X Stock
- Financials Immunovia AB
